News
Media
Conferences
Events
Partners
Publications
Resources
Biomarker Consortium
Subscribe

EGFR-Mutated NSCLC: Are Frontline Combinations the Future?

EP. 1: Molecular Testing in Metastatic NSCLC

ByEdgardo S. Santos Castillero, MD, FACP, Florida Precision Oncology,John V. Heymach, MD, PhD, MD Anderson Cancer Center

September 29th 2020

EP. 2: Metastatic NSCLC: The Role of Liquid Biopsy

ByEdgardo S. Santos Castillero, MD, FACP, Florida Precision Oncology,John V. Heymach, MD, PhD, MD Anderson Cancer Center

September 29th 2020

EP. 3: Molecular Testing Prior to Metastases

ByEdgardo S. Santos Castillero, MD, FACP, Florida Precision Oncology,John V. Heymach, MD, PhD, MD Anderson Cancer Center

September 29th 2020

EP. 4: Approved Frontline TKIs for EGFR-Mutated Disease

ByEdgardo S. Santos Castillero, MD, FACP, Florida Precision Oncology,John V. Heymach, MD, PhD, MD Anderson Cancer Center

September 29th 2020

EP. 5: The Use of TKIs in Patients With Brain Metastases

ByEdgardo S. Santos Castillero, MD, FACP, Florida Precision Oncology,John V. Heymach, MD, PhD, MD Anderson Cancer Center

September 29th 2020

EP. 6: Data Updates From the GioTag Study

ByEdgardo S. Santos Castillero, MD, FACP, Florida Precision Oncology,John V. Heymach, MD, PhD, MD Anderson Cancer Center

September 29th 2020

EP. 7: EGFR TKI Plus Chemotherapy Combination Strategy

ByEdgardo S. Santos Castillero, MD, FACP, Florida Precision Oncology,John V. Heymach, MD, PhD, MD Anderson Cancer Center

September 29th 2020

EP. 8: TKI Combination Clinical Trials: Practical Implications in US and UK

ByEdgardo S. Santos Castillero, MD, FACP, Florida Precision Oncology,John V. Heymach, MD, PhD, MD Anderson Cancer Center

September 29th 2020

EP. 9: TKI Plus Antiangiogenic Combination Therapy

ByEdgardo S. Santos Castillero, MD, FACP, Florida Precision Oncology,John V. Heymach, MD, PhD, MD Anderson Cancer Center

September 29th 2020

EP. 10: RELAY Trial Regimen Adverse-Event Overview

ByEdgardo S. Santos Castillero, MD, FACP, Florida Precision Oncology,John V. Heymach, MD, PhD, MD Anderson Cancer Center

September 29th 2020

EP. 11: EGFR-Mutated NSCLC: Looking Ahead

ByEdgardo S. Santos Castillero, MD, FACP, Florida Precision Oncology,John V. Heymach, MD, PhD, MD Anderson Cancer Center

September 29th 2020

Trending on OncLive

ctDNA Status Has Strong Prognostic Value, Outperforming pCR Status, in Early TNBC

Dato-DXd Hits Key Secondary Efficacy End Points in First-Line TNBC

FDA Grants Priority Review to Giredestrant for ER-Positive Early Breast Cancer

Retrospective Data Show Zanubrutinib May Less AFib Burden in Real-World CLL

Bispecific-Based Approaches Highlight Key Multiple Myeloma Data Set to Emerge at EHA 2026